Cargando…

2362. Emergency Department Resource Utilization After Implementation of a Dalbavancin Pathway for Skin and Soft-Tissue Infections

BACKGROUND: Dalbavancin has an extended duration of activity allowing for single-dose treatment of skin and soft-tissue infections (SSTI). An SSTI treatment pathway in the University of Maryland Medical Center (UMMC) Emergency Department (ED) was revised in December of 2016 to add dalbavancin for pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heil, Emily, Martinelli, Ashley, Oliver, Wesley, Claeys, Kimberly
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253304/ http://dx.doi.org/10.1093/ofid/ofy210.2015

Ejemplares similares

2362. Back to the Future: The Impact of Multi-Step Algorithm C. difficile Testing at a Large Tertiary Medical Center
por: Bork, Jacqueline, et al.
Publicado: (2019)

Impact of an Antimicrobial Stewardship and Emergency Department Initiated Dalbavancin Guideline for Patients with Acute Bacterial Skin and Soft-Tissue Infections
por: Burgess, Donna R, et al.
Publicado: (2017)

Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review
por: Bennett, Jason W, et al.
Publicado: (2008)

Complete Genome Sequence of Lysinibacillus sphaericus WHO Reference Strain 2362
por: Hernández-Santana, Alejandra, et al.
Publicado: (2016)

Dalbavancin in the Treatment of Bacteremia and Endocarditis in People with Barriers to Standard Care
por: Ajaka, Leama, et al.
Publicado: (2020)

PReS-FINAL-2362: The spectrum of childhood inflammatory brain diseases; an increasingly recognised field
por: Twilt, M, et al.
Publicado: (2013)

Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)
por: Leuthner, Kimberly D, et al.
Publicado: (2016)

267 Dalbavancin for the treatment of Streptococcal Skin Infections
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

2370. Dalbavancin Use in Emergency Department and Observation Unit to Prevent Inpatient Admission for Acute Bacterial Skin and Skin Structure Infection (ABSSI)
por: Ford, Jonathan, et al.
Publicado: (2018)

Dalbavancin
por: Barberán, José, et al.
Publicado: (2021)

314. A Retrospective Review of Dalbavancin Utilization at an Academic Medical Center
por: Napoli, Emma, et al.
Publicado: (2020)

1365. Clinical and Financial Implication of Dalbavancin Utilization on Length of Stay Avoidance in Acute Bacterial Skin and Skin Structure Infection
por: Kim, Sonia S, et al.
Publicado: (2021)

349. Diagnostic Testing and Antibiotic Utilization in Patients with COVID-19
por: Groft, Lauren, et al.
Publicado: (2021)

2380. Healthcare Resource Utilization for High-Risk Patients Treated With Dalbavancin in Physician Office Infusion Centers (POICs)
por: Luu, Quyen, et al.
Publicado: (2018)

Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization
por: Simonetti, Oriana, et al.
Publicado: (2021)

Using an Ordinal Approach to Compare Outcomes Between Vancomycin Versus Ceftaroline or Daptomycin in MRSA Bloodstream Infection
por: Barlow, Ashley, et al.
Publicado: (2021)

1828. Dalbavancin Utilization and Associated Clinical Outcomes: A Case-Series
por: Greckel, Meagan N, et al.
Publicado: (2022)

Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections
por: Bork, Jacqueline T., et al.
Publicado: (2019)

Role of Extracellular DNA in Dalbavancin Activity against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms in Patients with Skin and Soft Tissue Infections
por: Sivori, Francesca, et al.
Publicado: (2022)

1220. Is MIC all that matters? MIC Distributions of Ceftazidime and Cefepime in Ceftriaxone-Resistant E. coli and Klebsiella spp
por: Heil, Emily, et al.
Publicado: (2021)

Financial Analysis of Dalbavancin for Acute Bacterial Skin and Skin Structure Infections for Self-Pay Patients
por: Pizzuti, Adam G., et al.
Publicado: (2020)

PB2362: BEST PRACTICES ON EMPOWERING AND INVOLVING PATIENTS LIVING WITH HEMATOLOGICAL MALIGNANCIES ON THE DEVELOPMENT OF NOVEL PATIENT-REPORTED OUTCOME MEASURES
por: Vrontaras, N., et al.
Publicado: (2022)

In Vitro Activities of Ceftobiprole, Dalbavancin, Tedizolid and Comparators against Clinical Isolates of Methicillin-Resistant Staphylococcus aureus Associated with Skin and Soft Tissue Infections
por: Maraki, Sofia, et al.
Publicado: (2023)

Dalbavancin: a novel antimicrobial
por: Chen, A Y, et al.
Publicado: (2007)

589. Use of Dalbavancin in Facilitating Discharge of High Risk Patients in Low Resource Settings
por: Milgrom, Alexander
Publicado: (2020)

New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin
por: Juul, Janelle J, et al.
Publicado: (2016)

Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies
por: Dunne, Michael W., et al.
Publicado: (2015)

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Obese Population
por: Georgiades, Benjamin, et al.
Publicado: (2017)

The Safety and Efficacy of Dalbavancin and Active Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections
por: Giorgobiani, Manana, et al.
Publicado: (2022)

Utilization of Online Resources by Patients in an Ophthalmic Emergency Department
por: Hwang, Jodi C., et al.
Publicado: (2021)

Clinical Effectiveness and Pharmacokinetics of Dalbavancin in Treatment-Experienced Patients with Skin, Osteoarticular, or Vascular Infections
por: Stroffolini, Giacomo, et al.
Publicado: (2022)

Acute Bacterial Skin and Skin Structure Infections Treated with Intravenous Antibiotics in the Emergency Department or Observational Unit: Experience at the Detroit Medical Center
por: Claeys, Kimberly C., et al.
Publicado: (2015)

PB2362: THE EFFECT OF BODY MASS INDEX (BMI) ON THE PROGNOSIS OF DLBCL PATIENTS TREATED WITH R-CHOP: A REAL WORLD MOROCCAN EXPERIENCE
por: el Filali, Imane Ait, et al.
Publicado: (2023)

2362. SARS-CoV-2 Omicron Variants Associated with Less Severe Disease in Hospitalized Patients Irrespective of Baseline Risk Factors and Immunity
por: Lee, Austin, et al.
Publicado: (2023)

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Patients with Diabetes Mellitus
por: Nowak, Michael, et al.
Publicado: (2017)

Evaluation of Dalbavancin and Oritavancin as Cost-Effective Treatments of Acute Bacterial Skin and Skin Structure Infections in Hospitalized Patients
por: Koutsari, Christina, et al.
Publicado: (2017)

Pharmacist-Directed Use of Dalbavancin in Acute Bacterial Skin and Skin Structure Infections to Reduce Hospital Length of Stay
por: Jones, Bruce, et al.
Publicado: (2017)

Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs
por: Gonzalez, Pedro Luis, et al.
Publicado: (2018)

1556. Financial Analysis of Dalbavancin for Acute Bacterial Skin and Skin Structure Infections in a self-pay population
por: Murray, E Yancey, et al.
Publicado: (2020)

Clinical Management of Skin and Soft Tissue Infections in the U.S. Emergency Departments
por: Mistry, Rakesh D., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_muc2latso2en9tkmr3htc3lkfr